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Table 1. Factors that were found associated with serum cystain C after adjusting for uncorrected creatinine clearance (first column)
Adjusted for Ccr Adjusted for BSA corr Ccr Adjusted for height corr Ccr
Beta st err P Beta st err P beta st err P
Weight kg .002 2.79 × 10−4 <.001 .000 2.62 × 10−4 .212 .002 2.79 × 10−4 <.001
Height cm .002 4.66 × 10−4 <.001 .001 4.67 × 10−4 .022 .001 4.69 × 10−4 .146
Age years .004 2.87 × 10−4 <.001 .004 2.88 × 10−4 <.001 .004 2.87 × 10−4 <.001
Gendera −.066 .008 <.001 −.066 .008 <.001 −.066 .008 <.001
Smokinga .051 .006 <.001 .051 .006 <.001 .051 .006 <.001
Ln CRP mg/L .038 .003 <.001 .038 .003 <.001 .038 .003 <.001
In columns 2 and 3 the same associations are presented after adjusting for BSA corrected or height corrected creatinine clearance.
aReference for gender is male gender, and for smoking is nonsmokers.
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Reply from the Authors
Dr. Bo¨kenkamp comments on our message that it is
of importance to take height and weight into account
when using serum cystatin C level as a measure for re-
nal function [1]. We found that height and weight were
associated with serum cystatin C when we adjusted for
creatinine clearance (Ccr) uncorrected for body surface
area (BSA).They argue that the associations between
weight and height and cystatin C probably will disappear
when we adjust for BSA corrected Ccr instead of uncor-
rected Ccr. They understandably raise that question be-
cause GFR generally is normalized to 1.73m2 BSA (which
is determined by both height and weight), especially in
growing subjects.
We, by purpose, had chosen not to adjust for BSA cor-
rected Ccr because this might mask a potential effect of
obesity. In adults, weight generally has more impact on
BSA than height. This has led to the suggestion that it
would be better to use GFR measurements corrected for
height rather than BSA [2]. In Table 1, we therefore plot
the association of the linear regression model of weight
and height and cystatin C after adjusting for uncorrected
Ccr (first column), for BSA corrected Ccr (second col-
umn), and for height corrected Ccr(third column).
As expected, the associations of weight and height
with serum cystatin C were lower or even absent in the
model using BSA adjusted Ccr, but the association be-
tween weight and serum cystatin C remained identical in
the model, in which we adjusted for height corrected Ccr
in our adults of 28 to 75 years of age.
Bo¨kenkamp also questions what happens with the
other factors associated with cystatin C, that is age, gen-
der, smoking, and CRP when we adjust for BSA or
height corrected Ccr. As can be seen from the Table,
those associations remained completely identical in both
new models compared to the original model. This indi-
cates that factors other than body size are responsible for
the associations of age, gender, smoking, and CRP with
cystatin C.
We should realize that we presently accept serum cre-
atinine only as an appropriate marker of renal function
when we take into account age, gender, and weight. This
is common practice in the serum creatinine derived for-
mulas to estimate renal function. In that respect, it should
be welcomed that recently a formula has also been intro-
duced to calculate GFR (in mL/min) from plasma cys-
tatin C values (in mg/L). Based upon measurements of
serum cystatin C (by Dade Behring assay) and of iohexol
measured GFR, Larsson et al calculated GFR as (77.24 ×
serum cystatin C)−1.2623 [3]. Remarkably, these authors
did not take into account any of the above described vari-
ables in their formula.
Using that formula instead of serum cystatin C level,
the associations in the above-mentioned three models did
not change significantly. This implies that, when using cys-
tatin C as measure of renal function, a cystatin C–based
formula should be designed to take into account at least
age, gender, and weight, just as in the creatinine-based
formulas to estimate renal function.
In addition, further studies are needed to investigate
the association between inflammation (as reflected by
CRP) and cystatin C levels. Because CRP was found in-
dependently associated with serum cystatin C, and be-
cause CRP levels are found associated with progressive
atherosclerosis [4], it might well be that cystatin C is a
good marker for renal function because it, better than
creatinine, reflects the extent of atherosclerosis accom-
panying impaired renal function.
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Anemia treatment and decline
of renal function
To the Editor: In the August issue of Kidney Interna-
tional Gouva et al [1] reported a significant benefit in
terms of death or aggravation of renal failure in non-
diabetic patients with chronic renal failure and anemia
randomized to the early, systematic administration of ery-
thropoietin with a target hemoglobin (Hb) concentration
of 13 g/dL, compared with deferred treatment started
when Hb reached a concentration ≤9 g/dL.
Results of this well-designed study are welcome be-
cause they demonstrate a benefit of the correction of
anemia in chronic renal failure (CRF) on hard end points
(doubling of creatinine or creatinine of >8 mg/dL or ini-
tiation of renal replacement or death). This trial raises,
however, an ethical issue because American [2] and Eu-
ropean [3] guidelines published in 1997 and 1999 recom-
mended in predialysis patients a Hb concentration of 10
and 11 g/dL, respectively, based on evidence of a better
quality of life and cardiovascular protection [2, 3]. With
a baseline creatinine clearance of 26.7 ± 9.1 mL/min and
22.3 ± 6.0 mL/min in early and deferred treatment arms,
respectively, most patients in Gouva’s study were in the
target of guidelines. Moreover, this study leaves open two
important questions: the target Hb concentration and the
glomerular filtration rate (GFR) threshold for interven-
tion. It is necessary to determine if an Hb concentration
higher than recommended (≥13 g/dL) results in a slower
progression of CRF and is well tolerated. We need also
to evaluate the effects of correcting anemia earlier in the
course of CRF, when GFR is still >25 mL/min and the
correction of anemia can be expected to be more effective
on CRF progression.
The NEPHRODIAB2 study was designed to answer
these questions in type 2 diabetic patients with GFR 25
to 60 mL/min/1.73m2 and Hb 10 to 12.9 g/dL [4]. In this
randomized trial, primary end point is the decline in GFR
in normal (11-12.9 g/dL) versus high Hb concentration
(13-14.9 g/dL) arms after two years of follow-up. The
planned sample size is 204. Inclusions started in France
in February 2004.
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We thank Dr. Villar et al for their comments. Most ex-
pert guidelines at the time that our study was designed
would probably suggest treating anemia for hemoglobin
<10 g/dL [1] or even <11 g/dL [2]. However, as these
same guidelines had acknowledged up front, “the target
hemoglobin concentration perhaps represents the most
controversial single issue in the application of epoetin to-
day” [2]. Moreover, most of the available prior evidence
pertained to patients with more advanced renal disease
than in our study and/or patients with diabetes mellitus.
Finally, the outcomes were mostly centered on quality
of life, and it is well known that quality of life can be
subject to considerable measurement error and bias [3].
Thus, we felt it was a top priority to generate appropriate
evidence for the implementation of erythropoietin treat-
ment in patients with modest renal function impairment,
rather than perpetuate a debate with limited data. We
welcome the interesting NEPHRODIAB2 study that Dr.
Villar et al are conducting, and we look forward to see-
ing their results. We believe that similar studies may need
to be conducted also in nondiabetic patients with a sim-
ilar early level of renal dysfunction. However, studying
these patient populations, especially nondiabetic ones, is
challenging. Given the early stage of disease, very few
disease progression events are likely to occur even with
considerable follow-up, and the cost-benefit of chronic
